Home » ADVANCED VIRAL RESEARCH (ADVR) IS GRANTED US PATENT FOR RHEUMATOID ARTHRITIS
ADVANCED VIRAL RESEARCH (ADVR) IS GRANTED US PATENT FOR RHEUMATOID ARTHRITIS
July 17, 2006
Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that effective June 27, 2006, the company has received US patent approval for treatment of rheumatoid arthritis by administering Product R (AVR118), a peptide-nucleic acid preparation. Rheumatoid arthritis, a chronic inflammatory illness, is an autoimmune disease in which the immune system attacks normal tissue components as if they were invading pathogens. This illness affects about one percent of the world's population.
Genetic
Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct